Fertin
  • Delivery systems
    • Zapliq®
    • Compressed gum
    • Extruded gum
    • Lozenge
    • Pouch powder
    • Custom delivery systems and co-development
  • Application areas
    • Nicotine
    • Cannabinoids
    • Vitamins and dietary supplements
    • Oral care
    • Energy management
    • Pain management
    • Allergy
    • Cough and cold
    • Gastrointestinal
    • Sleep and relaxation
  • Services
    • Research and development
    • Manufacturing and packaging
    • Sensory optimisation
    • Regulatory and compliance
    • Quality control and assurance
    • Intellectual property
  • News & insights
    • News
    • Insights
  • Sustainability
  • About
    • Fertin Pharma Group
    • Fertin India
    • NordicCan
    • Tab Labs
  • Careers
  • Contact
  • Search
  • Account
  • Delivery systems
    • Zapliq®
    • Compressed gum
    • Extruded gum
    • Lozenge
    • Pouch powder
    • Custom delivery systems and co-development
  • Application areas
    • Nicotine
    • Cannabinoids
    • Vitamins and dietary supplements
    • Oral care
    • Energy management
    • Pain management
    • Allergy
    • Cough and cold
    • Gastrointestinal
    • Sleep and relaxation
  • Services
    • Research and development
    • Manufacturing and packaging
    • Sensory optimisation
    • Regulatory and compliance
    • Quality control and assurance
    • Intellectual property
  • News & insights
    • News
    • Insights
  • Sustainability
  • About
    • Fertin Pharma Group
    • Fertin India
    • NordicCan
    • Tab Labs
  • Careers
  • Contact
  • Search
  • Account
Fertin
Latest news
2021-12-16

Ready to start production of innovative oral CBD products

  With the Processing License from Health Canada in place, NordicCan is ready to start production of CBD products in Canada. “With the Processing License granted by Health Canada, we are ready to go into full-scale production beginning 2022 at our site, Cogent, located near Vancouver”, says NordicCan CEO Julie Malbaek. “Since we received our

2021-12-07

Novel opportunities with new cannabinoid patents

Four new patents open new doors to innovative and precise oral delivery of cannabinoids in the US and Canadian markets. The patents granted to NordicCan, a company in the Fertin Group, cover novel gum base formulations improving oral delivery of cannabinoids. The worldwide interest in cannabinoids for wellness and medical purposes is growing, and with

2021-09-16

Fertin Pharma announces closing of acquisition by Philip Morris International

Fertin Pharma A/S (“Fertin Pharma”), a leading developer and manufacturer of innovative pharmaceutical and well-being products based on oral and intra-oral delivery systems, today announced the closing of its acquisition by Philip Morris International Inc. (PMI) (NYSE: PM) for an enterprise value of DKK 5.1 billion (approximately USD 820 million[1] ). “We are excited to

2021-07-01

Fertin Pharma and associated companies acquired by Philip Morris International

Vejle, 1 July, 2021 EQT announced today that it has agreed to sell Fertin Pharma, a specialist contract development and manufacturing organization (CDMO) in innovative oral and intra-oral delivery technologies, to Philip Morris International (PMI) (NYSE: PM). With headquarters in Vejle, Denmark, Fertin Pharma is a leading specialist CDMO in innovative oral and intra-oral delivery

2021-05-19

An interview with Mie Drachmann, a junior specialist in the pharmaceutical industry

This article was originally published in Danish by the University of Southern Denmark (SDU) and adapted by Fertin Pharma. Read the original article here: Mie er junior specialist i lægemiddelbranchen (mitsdu.dk) Subject knowledge is indispensable, but personality and social skills also play a significant role when a company needs to find the right employee. Mie

2021-04-26

World Intellectual Property Day

IP – a vital framework to create healthier living Every year in April, the global community celebrates World Intellectual Property Day. At Fertin, we recognize the importance of putting Intellectual Property (IP) in the limelight. We believe that IP is a vital framework and powerful tool to advance new ideas and to stimulate cutting-edge research

2021-04-22

NordicCan Secures Two Patents issued by the Canadian Intellectual Property Office for the Administration of Cannabinoids through Oral Dosage Formats

NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, announced that the Canadian Intellectual Property Office has issued patent numbers CA 3,031,530 and CA 3,035,400 covering the use of cannabinoids within NordicCan’s extruded and compressed chewing gum formulations, including its unique bi-layered compressed gum format. “These patents

2021-03-11

COVID 19: A thank you message from the CEO

It has been more than one year since the COVID-19 pandemic hit the world and changed nearly every aspect of our existence. We are adjusting to a new reality in most parts of our lives, as businesses as well as individuals. Although there is still undoubtedly uncertainty in the days ahead, we would like to

2021-03-10

Health Canada Grants Cannabis Research License to NordicCan

VEJLE, Denmark—March 7, 2021—NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, has obtained approval a Research License from Health Canada under the Cannabis Act. The Research License is a key element in NordicCan’s strategy of obtaining the processing license for cannabinoid oral dosage formats from the

2021-03-10

NordicCan Secures Two New US Patents for the Administration of Cannabinoids through Oral Dosage Formats

VEJLE, Denmark—March 5, 2021—NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, today announced that the United States Patent and Trademark Office (USPTO) has issued it two patents: U.S. Patent No. 10,925,853 and US 10,933,017 cover the use of cannabinoids within NordicCan’s oral dosage formats Zapliq Chewable

Archive
  • 2021
  • 2020
  • 2019
Deliver active and functional ingredients to your consumer in a pleasurable and effective way
Dandyvej 19, DK-7100 Vejle, Denmark
+45 7215 1300  |  fertin@fertin.com
Follow us
How can we help?
Discuss your next product with our experts today
Dandyvej 19, DK-7100 Vejle, Denmark
+45 7215 1300  |  fertin@fertin.com
Fertin Pharma 2019. All Rights Reserved.
Disclaimer | Privacy Policy | Cookie Policy | Food Safety
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.